TABLE 1.
Baseline demographics among confirmed cases of COVID-19
| All (n = 70) | Positive Ab (n = 36) | Negative Ab (n = 34) | p-value | |
|---|---|---|---|---|
| Days from diagnosis to first serology test, median (IQR) | 47.50 (28.75–68.75) | 52 (31.75–67.75) | 42 (25.75–68.75) | .57 |
| Number of serology tests performed, median (IQR) | 1 (1–2) | 1 (1–2) | 1 (1–2) | .78 |
| Age in years, median n (IQR) | 57 (45–66) | 57 (43.5–68) | 56 (48–65) | .97 |
| Male sex, n (%) | 44 (63) | 27 (75) | 17 (50) | .03 |
| Race, n (%) | .9 | |||
| White | 32 (46) | 15 (42) | 17 (50) | |
| Black | 19 (27) | 11 (31) | 8 (24) | |
| Asian | 2 (3) | 1 (3) | 1 (3) | |
| Other, multiple, or declined | 17 (24) | 9 (25) | 8 (24) | |
| Hispanic Ethnicity, n (%) | 27 (39) | 12 (33) | 15 (44) | .35 |
| Organ Transplant, n (%) | .15 | |||
| Kidney (± pancreas) | 39 (56) | 16 (44) | 23 (68) | |
| Lung | 13 (19) | 7 (19) | 6 (18) | |
| Liver (± kidney) | 10 (14) | 8 (22) | 2 (6) | |
| Heart (± kidney) | 8 (11) | 5 (14) | 3 (9) | |
| Received kidney allograft | 43 (61) | 18 (50) | 25 (74) | .04 |
| Years from transplant to diagnosis, median n (IQR) | 3.21 (0.98–8.57) | 6.08 (2.53–11.61) | 1.51 (0.32–3.74) | <.001 |
| Within 1 month, n (%) | 3 (4) | 0 (0) | 3 (9) | .07 |
| Within 1 year, n (%) | 18 (26) | 3 (8) | 15 (44) | .001 |
| Comorbidities, n (%) | ||||
| HTN | 51 (73) | 24 (67) | 27 (79) | .23 |
| DM | 30 (43) | 14 (39) | 16 (47) | .49 |
| CKD | 53 (76) | 23 (64) | 30 (88) | .02 |
| Chronic lung disease | 15 (21) | 7 (19) | 8 (24) | .68 |
| HIV | 2 (3) | 1 (3) | 1 (3) | .97 |
| BMI >40 Kg/m2 | 5 (7) | 3 (8) | 2 (6) | .69 |
| Baseline immunosuppression, n (%) | ||||
| CNI | 52 (75) | 24 (67) | 28 (82) | .13 |
| Mycophenolate | 57 (81) | 27 (75) | 30 (88) | .16 |
| Steroids | 42 (60) | 19 (53) | 23 (68) | .2 |
| Belatacept | 15 (21) | 5 (14) | 10 (29) | .11 |
| IVIG ± Pheresis | 2 (3) | 0 (0) | 2 (6) | .14 |
| mTOR | 2 (3) | 2 (6) | 0 (0) | .16 |
| Thymoglobulin <3 mo | 10 (14) | 2 (6) | 8 (24) | .03 |
| >2 IS agents | 42 (60) | 17 (47) | 25 (74) | .03 |
| Treated ACR in 3 months prior to diagnosis, n (%) | 10 (14) | 2 (6) | 8 (24) | .03 |
| Immunoglobulin level (IgG) in 3 months prior to diagnosis, median n* (IQR) | 951 (804–1222) | 867 (796–1141) | 959 (818–1222) | .4 |
| Changes in Immunosuppression, n (%) | ||||
| Decrease or hold antimetabolite | 46 (66) | 22 (61) | 24 (71) | .4 |
| Decrease or hold CNI | 8 (11) | 3 (8) | 5 (15) | .4 |
| Therapy, n (%) | ||||
| Hydroxychloroquine | 39 (56) | 22 (61) | 17 (50) | .35 |
| Azithromycin | 25 (36) | 14 (39) | 11 (32) | .57 |
| Remdesivir | 6 (9) | 2 (5.6) | 4 (12) | .35 |
| High dose corticosteroids | 14 (20) | 6 (17) | 8 (24) | .47 |
| Tocilizumab | 6 (9) | 2 (6) | 4 (12) | .35 |
| Convalescent plasma trial | 4 (6) | 1 (3) | 3 (9) | .28 |
| Highest Level of Respiratory Support, n (%) | .77 | |||
| Room air | 41 (59) | 23 (64) | 18 (53) | |
| Nasal Cannula | 21 (30) | 10 (28) | 11 (32) | |
| NRB/high flow/BIPAP | 5 (7) | 2 (6) | 3 (9) | |
| Mechanical ventilation | 3 (4) | 1 (3) | 2 (6) | |
| Highest Level of Medical Support, n (%) | .62 | |||
| Outpatient | 27 (39) | 15 (42) | 12 (35) | |
| Medical Ward | 37 (53) | 19 (53) | 18 (53) | |
| ICU Admission | 6 (9) | 2 (6) | 4 (12) |
*
Immunoglobulin levels were available in 39 of 70 pts.